Aquestive Therapeutics, Inc. (AQST)
| Market Cap | 148.21M |
| Revenue (ttm) | 46.90M |
| Net Income (ttm) | -61.96M |
| Shares Out | 40.16M |
| EPS (ttm) | -1.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 811,937 |
| Open | 3.68 |
| Previous Close | 3.67 |
| Day's Range | 3.48 - 3.70 |
| 52-Week Range | 3.10 - 7.00 |
| Beta | 3.33 |
| Analysts | Buy |
| Price Target | 15.00 (+306.5%) |
| Earnings Date | Nov 2, 2021 |
About AQST
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for AQST stock is "Buy." The 12-month stock price forecast is 15.00, which is an increase of 306.50% from the latest price.
News
Why Aquestive Therapeutics Dived by 29% Today
A decision on a crucial regulatory filing is being delayed indefinitely.
See Why Aquestive Therapeutics Shares Are Down More Than 30%
The FDA has notified Aquestive Therapeutics Inc (NASDAQ: AQST) that the agency is still considering the regulatory issues related to the approvability of Libervant and will not be ready to take action b...
SHAREHOLDER ALERT: Robbins LLP Investigates Aquestive Therapeutics, Inc. (AQST) on Behalf of Shareholders
SAN DIEGO & WARREN, N.J.--(BUSINESS WIRE)---- $AQST #Libervant--Aquestive Therapeutics, Inc. (AQST) May Have Misled Investors About the Likelihood of Approval of its New Drug Application for Libervant
Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 f...
WARREN, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options
Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.
Aquestive Therapeutics Added to NASDAQ Biotechnology Index
WARREN, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet...
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 7.50% and 10.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year ...
WARREN, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patien...
Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prod...
WARREN, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 an...
WARREN, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and...
WARREN, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference
WARREN, N.J., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 21.43% and 44.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year R...
WARREN, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patien...
Earnings Preview: Aquestive Therapeutics (AQST) Q2 Earnings Expected to Decline
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Stocks To Watch With The Stock Market Down Today
Which Penny Stocks Are Investors Watching After the Stock Market Crash? The post 4 Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | P...
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) ...
WARREN, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film
WARREN, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics Announces Leadership Transition of Chief Financial Officer
WARREN, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics to Participate in JMP Securities and BMO Capital Market Investor Conferences
WARREN, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics to Participate in 2021 RBC Capital Markets Global Healthcare Conference
WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patien...
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 6.82% and 21.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
WARREN, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patient...
DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. an...
Los Angeles, California--(Newsfile Corp. - April 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...